Loading...
Market
Will Syndax Pharmaceuticals' stock rise over 10% by end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial platforms such as Bloomberg or Yahoo Finance
Story
FDA Approves Syndax's Revuforj for Acute Leukemia, Shares Rise 4%
Nov 15, 2024, 10:53 PM
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), developed by Syndax Pharmaceuticals, for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation. This approval, announced on Friday, is significant as Revuforj is the first and only menin inhibitor to treat this specific type of leukemia. The drug is approved for both adult and pediatric patients one year and older. Following the announcement, Syndax Pharmaceuticals' shares rose by 4% in after-hours trading.
View original story
Similar markets
No change • 25%
Improved by 1-5 ranks • 25%
Improved by 6-10 ranks • 25%
Improved by more than 10 ranks • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
